Last reviewed 2026-06-01 · How we verify

Miscellany

Ana Palanca · Phase 2 active Small molecule ✓ Verified Jun 2026

Miscellany is a Small molecule drug developed by Ana Palanca. It is currently in Phase 2 development.

Miscellany refers to a collection of various pieces of writing by different authors, often including pieces on multiple subjects and in different forms. This term is unrelated to the medical concept, which is a collection of verified facts about a substance or treatment, such as GLP-1RA, SGLT2i, and Insulin, used to study conditions like Type 2 Diabetes and Obesity.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Miscellany
Sponsor	Ana Palanca
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Miscellany CI brief — competitive landscape report
Miscellany updates RSS · CI watch RSS
Ana Palanca portfolio CI

Frequently asked questions about Miscellany

What is Miscellany?

Miscellany is a Small molecule drug developed by Ana Palanca.

Who makes Miscellany?

Miscellany is developed by Ana Palanca (see full Ana Palanca pipeline at /company/ana-palanca).

What development phase is Miscellany in?

Miscellany is in Phase 2.

Manufacturer: Ana Palanca — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing